Variant,CDRH3 Sequence,RNN P(Binder),CNN P(Binder),LD,K_D (nM),k_a (1/Ms),k_d (1/s)
1,WQEAAFYAHD,0.833,0.930,5,3.31,2.2E+05,7.3E-04
2,YGGRGMYQLE,0.906,0.973,6,1.74,2.9E+05,5.0E-04
3,WNQLGMYVND,0.874,0.888,6,3.36,2.2E+05,7.5E-04
4,YGMRGLYAYE,0.942,0.948,6,1.47,3.1E+05,4.6E-04
5,WMETGFYTHD,0.895,0.966,5,0.14,1.1E+05,1.4E-05
6,WNAPSFYAND,0.885,0.977,5,7.43,3.0E+05,2.2E-03
7,WOQGIGLYELD,0.942,0.889,5,1.90,3.1E+05,6.2E-04
8,WAMLGMYAHD,0.847,0.779,5,2.32,3.0E+05,7.0E-04
9,YQANGLYAYE,0.959,0.886,7,9.77,4.3E+05,4.2E-03
10,YRAVGFYTND,0.783,0.871,6,0.94,2.6E+05,2.4E-04
11,WAPYGLYAHD,0.948,0.959,5,1.28,2.9E+05,3.7E-04
12,WDGPAFYELD,0.860,0.936,5,31.1,1.0E+05,3.2E-03
13,WGIHSFYEHD,0.844,0.869,5,0.54,1.8E+05,9.6E-05
14,YGEYGMYVNK,0.888,0.870,7,1.24,3.2E+05,7.0E-04
15,WRDRGFYEYD,0.858,0.974,5,0.71,2.6E+05,1.9E-04
16,WEEYGLYVHD,0.933,0.992,6,1.98,7.8E+04,1.5E-04
17,YASAGMYTHD,0.927,0.883,7,4.92,3.4E+05,1.7E-03
18,YGDAGMYALK,0.973,0.995,7,4.84,3.7E+05,1.8E-03
19,WQLGGMYTHD,0.919,0.941,6,7.55,1.6E+05,1.2E-03
20,WNSDGLYAYE,0.864,0.961,5,7.22,3.3E+05,2.4E-03
21,WQRGGFYVND,0.956,0.993,5,0.51,2.5E+05,1.3E-04
22,YGARGFYQND,0.892,0.789,5,6.33,4.4E+05,2.8E-03
23,YAGPGMYTNQ,0.870,0.830,7,3.37,2.4E+05,8.2E-04
24,WNPHGLYVND,0.939,0.974,6,1.11,2.4E+05,2.7E-04
25,YGSNGLYANQ,0.914,0.908,6,7.25,3.1E+05,2.3E-03
26,WPKVGLYTND,0.853,0.865,6,2.46,2.6E+05,6.3E-04
27,WGIVSFYEND,0.871,0.873,5,3.90,2.0E+05,8.0E-04
28,YSMPGMYTNA,0.848,0.938,8,3.60,2.6E+05,9.5E-04
29,WAEAGMYEFD,0.880,0.915,6,3.60,1.3E+05,4.5E-04
30,WPMCGMYTHD,0.835,0.855,6,3.86,1.1E+05,4.4E-04
Trastuzumab,WGGDGFYAMD,0.962,0.938,0,0.40,2.5E+05,1.0E-04
